| Added by | pmartino |
|---|---|
| Group name | EquipePM |
| Item Type | Journal Article |
| Title | Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study |
| Creator | Taibi et al. |
| Author | Abdelkader Taibi |
| Author | Olivia Sgarbura |
| Author | Martin Hübner |
| Author | Sylvia M. Bardet |
| Author | Mohammed Alyami |
| Author | Naoual Bakrin |
| Author | Sylvaine Durand Fontanier |
| Author | Clarisse Eveno |
| Author | Basile Pache |
| Author | Marc Pocard |
| Author | Hugo Teixeira Farinha |
| Author | Emilie Thibaudeau |
| Author | Frederic Dumont |
| Author | Olivier Glehen |
| Abstract | BACKGROUND: This retrospective multicenter cohort study compared the feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-Ox) with or without intraoperative intravenous 5-fluorouracil (5-FU) and leucovorin (L). METHODS: Our study included consecutive patients with histologically proven unresectable and isolated colorectal peritoneal metastases (cPM) treated with PIPAC-Ox in seven tertiary referral centers between January 2015 and April 2020. Toxicity events and oncological outcomes (histological response, progression-free survival, and overall survival) were compared between patients who received intraoperative intravenous 5-FU/L (PIPAC-Ox + 5-FU/L group) and patients who did not (PIPAC-Ox group). RESULTS: In total, 101 patients (263 procedures) were included in the PIPAC-Ox group and 30 patients (80 procedures) were included in the PIPAC-Ox + 5-FU/L group. Common Terminology Criteria for Adverse Events v4.0 grade 2 or higher adverse events occurred in 48 of 101 (47.5%) patients in the PIPAC-Ox group and in 13 of 30 (43.3%) patients in the PIPAC-Ox + 5-FU/L group (p = 0.73). The complete histological response rates according to the peritoneal regression grading score were 27% for the PIPAC-Ox + 5-FU/L group and 18% for the PIPAC-Ox group (p = 0.74). No statistically significant differences were observed in overall or progression-free survival between the two groups. CONCLUSIONS: The safety and feasibility of PIPAC-Ox + 5-FU/L appears to be similar to the safety and feasibility of PIPAC-Ox alone in patients with unresectable cPM. Oncological outcomes must be evaluated in larger studies. |
| Publication | Annals of Surgical Oncology |
| Volume | 29 |
| Issue | 8 |
| Pages | 5243-5251 |
| Date | 2022-08 |
| Journal Abbr | Ann Surg Oncol |
| Language | eng |
| DOI | 10.1245/s10434-022-11577-2 |
| ISSN | 1534-4681 |
| Short Title | Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases |
| Library Catalog | PubMed |
| Extra | PMID: 35318519 |
| Tags | Aerosols, clinic, Cohort Studies, Colorectal Neoplasms, Feasibility Studies, Fluorouracil, Humans, Leucovorin, Peritoneal Neoplasms |
| Date Added | 2023/04/06 - 17:57:27 |
| Date Modified | 2024/03/01 - 09:41:21 |
| Notes and Attachments | Full Text (Attachment) PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
